As one of Africa’s largest pharmaceutical markets — trailing only South Africa by value, and among the continent’s largest by population and consumption volume — Nigeria nonetheless leans heavily on imports to bridge a wide domestic supply gap, with roughly 70 per cent of medicines still sourced from overseas to meet its healthcare needs.
However, some local drug manufacturing companies, such as Fidson, May & Baker, and Mecure Industries, continue to overcome local manufacturing challenges to ensure local drug production and even export some of the locally produced drugs.
Yet, even the local drug manufacturing market is at the mercy of importation as it sources more than 90 per cent of its active pharmaceutical ingredients and excipients overseas.
Population growth, the pressure of urbanisation and increasing healthcare awareness are stoking demand for medicines in Nigeria, notably over-the-counter drugs which are seen taking up 69.4 per cent of total market share this year.
From $2 billion to $3.3 billion, estimates diverge as to the size of the Nigerian pharma market, with compound annual growth rate (CAGR) put at 6.5 per cent from 2025 to 2029.
Fidson’s dominance
On the exit of British multinational biopharma firm GlaxoSmithKline from Nigeria in 2023, the active pharmaceutical companies listed on the Nigerian Exchange are now four, namely Fidson Healthcare, May & Baker, Mecure Industries and Neimeth. That is only a fragment, considering that over 120 functional drugmakers altogether operate in Nigeria.
Fidson, which has a contract manufacturing relationship with Haleon, a British multinational consumer health giant and producer of brands such as Sensodyne, Panadol, Advil and Centrum, has led the publicly quoted pharma market for quite a while.
It holds the biggest slice of that market, alone accounting for well above half of the market share in the quarter to March 2026, when revenue soared to N42.6 billion year on year from N35 billion.
Mecure Industries, May & Baker (where Theophilus Danjuma, a former chief of army staff and minister of defence, is the biggest shareholder) and Neimeth came in tow, recording N20.2 billion, N8.4 billion and N1.8 billion in that order.
Little as it looks, exports by Fidson, at N1.8 billion, constituted only 4.3 per cent of revenue, but was a vast progress over the N146.5 million earned in the same period of the previous year.
Fidson’s topline performance in the period, as in recent years, built on a domestic prescription drug market boom, which Statista forecasted to touch $2.9 billion in sales in 2025 and thereafter advance at an annual growth rate of 3.6 per cent through 2029.
Ethical drugs, which have secured a place for themselves as the lifeblood of revenue, alone contributed 56.3 per cent of turnover.
For the financial year 2025, annual revenue climbed to an all-time peak of N119.1 billion from N84.1 billion, 53.3 per cent higher than that of Mecure, its closest rival.
Investment management firm Cardinal Stone has estimated that revenue for Fidson recorded a CAGR of around 28.5 per cent from FY 2021 to FY2024.
Beyond the favourable market dynamics, sales growth has reaped gains in no small measure from the forward-looking sectoral reforms of a government that is dreaming of ramping up the local share of national drug production to 70 per cent by 2030.
Nigeria’s pharma industry watchdog, the National Agency for Food and Drug Administration and Control, issued a provisional approval in April for R21 Malaria Vaccine to be marketed in Nigeria.
The push cleared the hurdle for a deal between Fidson and Serum Institute of India Pvt Limited, the maker of the vaccine, targeting prevention of clinical malaria in children aged 5 to 36 months and reduction of malaria-related mortality in tropical Africa.
In September 2024, the company reached a joint venture pact with Chinese companies Jiangsu Aidea Pharma, Nanjing PharmaBlock, and the Beijing-based China-Africa Development Fund to set up a facility for the manufacturing of HIV drugs in the Lekki Free Trade Zone in Lagos, aiming for West African pharmaceutical markets.
The management took its international partnership further last September when it had an agreement with Ohara Pharmaceutical Co. Limited.
The move would enable the Tokyo-based company to support Fidson’s capital raise and offer advisory support “based on insights from the Japanese pharmaceutical industry that will expand the capabilities of Fidson to produce more specialised medicines for the management of diverse disease conditions.”
Profit After Tax
Fidson’s post-tax profit went up by 39.4 per cent to N4.6 billion in Q1 2026, compared to a year ago, helped by a stronger sales expansion and, in part, by cost management. Mecure and May & Baker jointly came second, each reporting N1.3 billion, while Neimeth posted N113.4 million.
After-tax profit for 2025 grew to N9.9 billion from N4.4 billion. The company was followed by Mecure (N6.5 billion), May & Baker (N4.4 billion) and Neimeth (N976.4 million).
“Notably, during the period, the company commenced the export of its products, earning an additional N523.1 million in revenue,” Cardinal Stone stated in a research note in January on the 2025 rreport.
The Financial Times, in its African Fastest Growing Companies’ list for 2024, ranked Fidson 65th at a CAGR of 42.1 per cent. The company took the 67th position the following year with a CAGR of 42.6 per cent.
EBIT Margin
EBIT margin, which shows the operational profitability of a company by measuring its core profit in proportion to revenue, stood at 19.4 per cent for Fidson in the first quarter of the year, slightly up from Q1 2025 level of 18.9 per cent.
Neimeth led in this performance parameter, scoring 32.4 per cent, followed by Mecure (22.5 per cent) and May & Baker (21.3 per cent).
Fidson reported 18.4 per cent in EBIT margin for 2025, significantly higher than 5.2 per cent in 2024.
NET PROFIT MARGIN
Fidson’s net profit margin stood above all its peers’ but May & Baker’s (15.2 per cent) in the first quarter of 2026 as it jumped to 10.7 per cent from 9.3 per cent a year ago. Mecure reported a net profit margin of 6.7 per cent in the period, while Neimeth recorded 6.5 per cent.
For FY2025, the company posted a net profit margin of 8.3 per cent, up from 5.2 per cent in the corresponding period of the preceding year.
TOTAL ASSETS
The company is regarded as Nigeria’s biggest drugmaker on the strength of its asset base, which topped N93.7 billion in the period under review, increasing by 16.7 per cent year on year.
That was spurred largely by a more than twofold surge in trade & other receivables and, in part, by property, plant and equipment, following increased construction work in progress.
Total assets stood at N80.3 billion as of FY2025 and at N73.5 billion at FY2024.
Last December, Fidson launched a N21 billion rights issue, which was oversubscribed by 117 per cent, to raise capital to beef up production capacity, accelerate its pan-African expansion and deleverage its balance sheet.
Mecure Industries’ total assets for the period rose 36.4 per cent to N81.3 billion, May & Baker’s climbed by 1.5 per cent to N26.8 billion, while Neimeth’s jumped by 13.7 per cent to N14.1 billion.
Fidson’s ROAE dropped to 7 per cent from 12.8 per cent as its shareholder fund sharply expanded at a rate disproportionate to its net profit during the period, diluting the indicator. As a financial metric, ROAE implies how effectively the shareholder fund of a company has been used in earning profit over a period of time.
For FY2025, ROAE stood at 37.6 per cent, up from 28.9 per cent the year before.
May & Baker recorded an ROAE of 8.9 per cent within the period, down from 10.9 per cent in the first quarter of 2025. Mecure reported 6.5 per cent, up from 4.5 per cent, while Neimeth recorded 4.2 per cent, compared with 6.8 per cent a year earlier.
RETURN ON AVERAGE ASSETS (ROAA)
Fidson topped others in terms of ROAA, an indicator of how well a company puts its assets to use in generating profit, scoring 5.2 per cent in Q1 2026, relative to 4.2 per cent a year ago.
It recorded 12.9 per cent for FY2025 and 8.5 per cent for FY2024.
May & Baker came next at 4.9 per cent ROAA in Q1 2026, up from 4.5 per cent, while Mecure fell to 1.6 per cent from 4.1 per cent. Neimeth dropped to 0.8 per cent from 0.9 per cent.
Editor’s Note: This is a Native Advertising story.
Discover more from Premium Times Nigeria
Subscribe to get the latest posts sent to your email.
Insecurity has been identified as one of the “greatest obstacles” to containing the Ebola outbreak in the Democratic Republic of the Congo (DRC), where more than 11,000 cases and 5,400 deaths have been reported.
The World Health Organisation (WHO), in a news release publishedon 15 November, said attacks on health workers and facilities, displacement and difficulties reaching remote communities were disrupting efforts to contain the outbreak.
The outbreak, caused by the Bundibugyo virus, has spread to 67 health zones across eight provinces, with between 400 and 500 new cases reported weekly.
“Children account for more than a quarter of confirmed cases and one third of deaths. Seven in 10 children under five with confirmed Ebola have died,” it noted.
Attack on healthcare
According to the WHO, a recent armed attack in Cantine-Aloya killed 66 civilians, including three health workers, while three health facilities were looted.
The attack also resulted in more than 1,000 contacts being lost to follow-up, with three confirmed cases still unaccounted for. Another attack on the town was reported on 11 November.
According to WHO, more than 80 attacks on healthcare have been recorded since the outbreak was declared.
“A halt in hostilities is urgently needed to protect communities and health workers, and to safeguard the progress made over the past six months,” it noted.
The WHO said about two-thirds of confirmed deaths occurred in communities, suggesting that many infections were being identified too late for patients to receive timely treatment.
Cross-border transmission concerns
WHO also highlighted the risk of the outbreak spreading beyond the DRC, following recent imported cases in Kenya and Nigeria.
The agency said cross-border collaboration has strengthened surveillance, information-sharing and coordination among affected and at-risk countries.
“Recent imported cases in Kenya and Nigeria underscore the continuing risk of spread beyond national borders. Delays in paying frontline health workers and responders create tension and slow the response,” it said.
WHO said the developments underscored the need for neighbouring countries to maintain surveillance and preparedness, particularly around high-risk border areas.
Response gains
Despite the challenges, WHO said efforts had slowed transmission in some of the outbreak’s initial hotspots, including Mongbwalu, Nyankunde, Nizi, Rwampara and Butembo.
Diagnostic capacity has expanded from two laboratories to more than two dozen, while nearly 2,000 treatment beds are available across 104 treatment and transit centres.
About 3,000 people have recovered from the disease, while more than 17,000 community health workers and 46,000 community actors have been trained to support the response.
WHO said sustained funding, safe access for health workers and greater community participation would be essential to reaching areas that remain difficult to access and bringing the outbreak under control.
In Nigeria, the index patient evacuated to Switzerland has recovered and been discharged from hospital. At the same time, all 62 people identified as contacts have completed the mandatory 21-day monitoring period without any secondary infection.
The Nigeria Centre for Disease Control and Prevention (NCDC) disclosed this on 13 November, saying the patient tested negative for the virus after receiving further treatment in Switzerland.
NCDC Director-General, Jide Idris, said 13 of the 62 contacts developed fever or other symptoms during monitoring, but all tested negative. Seven suspected Ebola cases reported in five states were also investigated, with none testing positive.
“However, it is important to note that the completion of contact monitoring does not, by itself, constitute a formal declaration that an outbreak is over. Such a determination must be based on the applicable public health criteria and the findings of ongoing surveillance,” it noted.
“Nigeria therefore remains vigilant, particularly given the continued occurrence of Ebola virus disease in the DRC.”
Discover more from Premium Times Nigeria
Subscribe to get the latest posts sent to your email.
Médecins Sans Frontières (MSF) has warned that shortages of a lifesaving medicine are forcing medical teams to ration treatment for diphtheria patients in northern Nigeria, where more than 28,000 confirmed infections and 1,100 deaths have been reported this year.
The warning comes as figures attributed to the Nigeria Centre for Disease Control and Prevention (NCDC) show that the outbreak continues to spread, particularly among children who are unvaccinated or have not received all their recommended vaccine doses.
In a statement issued on Friday, MSF said supplies of diphtheria antitoxin (DAT), which neutralises the toxin responsible for potentially fatal complications, were dangerously low.
The organisation called on federal and state authorities, donors and international partners to urgently secure additional medicines and vaccines, ensure their timely clearance at ports and improve distribution to affected communities.
Treatment shortage threatens patients
MSF’s Medical Coordinator in Nigeria, David Kizito, warned that the shortage could compromise the treatment of severely ill patients.
“Our stocks are dangerously low, and we risk being unable to treat children and save lives as the outbreak continues,” he said.
MSF photograph of a healthcare worker examining a diphtheria patient at the Infectious Disease Hospital in Amanawa, Sokoto, on 8 October 2026
Diphtheria is a vaccine-preventable bacterial infection that can cause fever, sore throat and a thick membrane in the throat, sometimes obstructing breathing. Severe infections can damage the heart, nerves and kidneys.
According to the World Health Organisation (WHO), diphtheria antitoxin neutralises toxins circulating in the bloodstream, while antibiotics help eliminate the bacteria and reduce transmission.
Early administration of antitoxin is particularly important because it cannot reverse damage once the toxin has entered body cells.
MSF said limited global production and inconsistent availability had left treatment facilities struggling to obtain adequate supplies.
However, the organisation did not specify which facilities had exhausted their stocks, how many patients had been unable to obtain treatment or whether any deaths were directly attributable to the shortages.
Nigeria records 1,126 deaths
The warning comes amid a prolonged outbreak that began in late 2022.
PREMIUM TIMES reports that a situation report issued on 11 November by the International Federation of Red Cross and Red Crescent Societies(IFRC) and the Nigerian Red Cross Society, citing NCDC data, indicates that Nigeria recorded 37,529 suspected diphtheria cases, 28,151 confirmed infections and 1,126 deaths in 2026 as of 7 November.
The report said the outbreak had affected 26 states and the Federal Capital Territory, covering 361 local government areas.
Kano accounted for 12,008 confirmed cases, approximately 43 per cent of the national total.
The figures are substantially higher than those in MSF’s latest statement, which relied on NCDC statistics from 9 August, when 406 deaths had been reported for 2026.
The difference reflects reporting from separate periods and may include subsequent updates to surveillance records.
Katsina: 70 severe cases in 18 days
In Katsina State, MSF reported managing 86 diphtheria cases between 26 October and 12 November, including 70 classified as severe and 16 as non-severe.
Severe infections accounted for approximately 81 per cent of the patients managed by its teams during the period, although the figures do not represent the severity of all diphtheria infections recorded across the state.
MSF said its teams also reached 1,315 contacts through surveillance and contact-tracing activities. Of these, 1,301 received vaccinations, while 1,311 were given preventive antibiotics.
The organisation did not provide the locations of the cases or a breakdown of recoveries and deaths.
The development follows earlier concerns about the capacity of health facilities to manage the outbreak.
On 31 August, PREMIUM TIMES reported that the Federal Teaching Hospital (FTH), Katsina, was struggling with an influx of suspected and confirmed diphtheria patients, leaving its children’s ward under considerable pressure.
The hospital attributed the overcrowding partly to referrals from other facilities across the state.
In response, the federal government announced an emergency multi-agency task force to strengthen surveillance, immunisation and access to treatment in Katsina and Kano.
The intervention included plans to supply additional antitoxin, antibiotics, medical personnel and protective equipment to FTH Katsina.
Authorities also announced plans to establish treatment annexes across Katsina’s three senatorial districts — Katsina, Daura and Funtua — to reduce pressure on the referral hospital.
MSF’s latest statement did not indicate whether those facilities had become operational or how much additional antitoxin had been delivered since the intervention was announced.
Zamfara vaccine shortage
In neighbouring Zamfara State, MSF said its supported facilities in Gusau recorded more than 671 diphtheria admissions over approximately one month beginning on 6 October.
Most patients were children, while four out of every five had not been vaccinated.
The organisation also reported a substantial shortfall in vaccine supplies for an emergency immunisation campaign.
Of the 90,000 doses required, only 25,000 had been supplied, representing approximately 28 per cent of the stated requirement.
MSF said it was working with government health authorities to secure the outstanding doses and expand vaccination activities.
The shortfall highlights the continuing difficulties facing efforts to protect children against the disease.
In October, PREMIUM TIMES reportedthat the Executive Director of the National Primary Health Care Development Agency (NPHCDA), Muyi Aina, said about 93 per cent of children affected by recent diphtheria outbreaks had not received their full recommended vaccine doses.
Mr Aina said some had never been vaccinated, while others had received fewer than the three recommended doses. He identified misinformation and vaccine hesitancy among the challenges affecting immunisation uptake.
MSF’s response
Despite the challenges, MSF said its teams had treated more than 9,000 diphtheria patients through facility-based and community interventions since the beginning of its 2026 response.
In Kano, the organisation supported vaccination campaigns in April and June, administering more than 835,000 doses to children in partnership with the state Ministry of Health.
It also supported two vaccination rounds in Sokoto between February and April, reaching 49,018 children under 15.
The organisation said it was supporting treatment, surveillance, infection prevention and vaccination efforts in several northern states, alongside government health authorities.
MSF called for increased global production of diphtheria antitoxin and sustained investment in routine childhood immunisation to prevent further outbreaks.
The latest warning also draws renewed attention to the emergency measures announced by the federal government in August, particularly the delivery of antitoxin supplies and the proposed expansion of treatment facilities in Katsina.
The extent to which those interventions have improved access to treatment remains to be established.
Discover more from Premium Times Nigeria
Subscribe to get the latest posts sent to your email.